$GMRS

GMR Solutions, Inc. Class A (GMRS) Gets a Buy from Barclays

Barclays analyst Andrew Mok maintained a Buy rating on GMR Solutions, Inc. Class A (GMRS) with a $16.00 price target. Goldman Sachs also issued a Buy rating, while Morgan Stanley assigned a Hold. GMRS reported Q2 revenue of $1.49B and a GAAP net loss of $28.28M.

Original reporting
Published Aug 29, 2026, 8:37 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 30, 2026, 4:58 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GMR Solutions, Inc. Class A (GMRS) Gets a Buy from Barclays — source image
Decision brief

The 30-second read

$GMRSNeutralMed
01

Why it matters

Analyst upgrades could offset earnings disappointment, creating a short‑term trade opportunity.

02

Market read

Earnings and rating update provide fresh data for traders in the healthcare small‑cap space.

03

What to watch

No guidance provided; market may price in future earnings risk.

Relevance 6/10Novelty 7/10Timing: pre-market

Background

GMR Solutions reported Q2 2026 results and received mixed analyst ratings.

Company-level read

Ticker impact

$GMRSNeutralMedium confidence
Context

Barclays maintains a Buy rating and sets a $16 price target; earnings release shows $1.49B revenue and a $28.28M loss.

Expected impact

Possible modest price rise on the buy rating, but downside risk from loss.

Evidence & confidence

Buy rating adds support, but loss signals earnings weakness.

Market effects

Healthcare sector may see slight lift from analyst coverage of peers.

US small‑cap healthcare stocks could see modest interest.

Limited to US investors.

Counterpoint

Loss may outweigh rating upgrade; consider short position.

Key entities

  • GMR Solutions, Inc. Class A

    Healthcare services provider listed on NYSE.

  • Barclays

    Maintained Buy rating with $16 target.

Related articles

$GMRSMed

GMR Solutions Inc. (GMRS): Results of Operations and Financial Condition

GMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance LEWISVILLE, Texas (August 12, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of em

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

$GMRSMedAI 9/10

Full Transcript: GMR Solutions Q1 2026 Earnings Call - GMR Solutions (NYSE:GMRS)

GMR Solutions (NYSE:GMRS) reported Q1 2026 revenue of $1.46 billion (+6.6% YoY) and adjusted EBITDA of $305 million (+9.7%). The company said its recent IPO leaves net leverage around 3.5x. It cited a 47% rise in 911 nurse navigation calls and nearly $47 million in incremental annualized revenue from new agreements. 2026 guidance targets $5.89–$6.18 billion revenue and high single-digit adjusted EBITDA growth.

$LULUMed

JPMorgan resets Lululemon stock price target by 38%

JPMorgan cut Lululemon's (LULU) price target by 38% to $95, citing weak Q2 results and lower guidance. Revenue fell 4% to $2.4B, with North America and China sales declining. LULU stock is down 80% from highs. Boss maintained a 'Neutral' rating, noting challenges and high marketing costs.

$SUPVMed

Supervielle (SUPV) Swings Back To Profit As Layoffs Reshape The Bank

Grupo Supervielle (SUPV) reported a net income of AR$12.8 billion for Q2, reversing a prior loss, driven by a 17% workforce reduction and cost-cutting. Adjusted net income was AR$36.2 billion, with an adjusted ROAE of 12.4%. Lending metrics improved, with net interest income up 13.1% and NPL ratio at 5.5%. However, the bank posted a net loss of AR$5.4 billion for H1, with ROAA at 0.6% for Q2 and -0.1% for H1.

$DELLHighAI 9/10

Dell Stock Jumped 15% Last Week. Here's Why This Top AI Stock Is Still a Buy

Dell's stock rose 15% after reporting a 58% revenue increase to $47B, driven by AI infrastructure demand. AI-optimized server sales doubled to $16.4B, and traditional server revenue surged 122% to $10.5B. Adjusted earnings per share rose 203% to $7.04. Dell raised its full-year guidance, expecting 69% revenue growth to $192B and 148% earnings growth to $25.50 per share.